Jim Simons
RYTM icon

Jim Simons’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jim Simons’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.58M Sell
68,281
-189,730
-74% -$17.2M 0.01% 1208
2026
Q1 		$22.4M Sell
258,011
-83,182
-24% -$8.09M 0.04% 606
2025
Q4 		$36.5M Sell
341,193
-205,400
-38% -$21.8M 0.06% 385
2025
Q3 		$55.2M Buy
546,593
+231,700
+74% +$21.5M 0.07% 320
2025
Q2 		$19.9M Buy
314,893
+300,781
+2,131% +$18.4M 0.03% 719
2025
Q1 		$748K Buy
+14,112
New +$783K ﹤0.01% 2569
2022
Q2 		– Sell
-23,100
Closed -$266K – 4521
2022
Q1 		$266K Buy
+23,100
New +$203K ﹤0.01% 3526
2021
Q3 		– Sell
-52,200
Closed -$1.02M – 3791
2021
Q2 		$1.02M Buy
52,200
+3,200
+7% +$66.4K ﹤0.01% 2654
2021
Q1 		$1.04M Buy
49,000
+39,000
+390% +$1.13M ﹤0.01% 2595
2020
Q4 		$297K Sell
10,000
-187,000
-95% -$4.75M ﹤0.01% 3038
2020
Q3 		$4.27M Sell
197,000
-38,900
-16% -$892K ﹤0.01% 1663
2020
Q2 		$5.26M Buy
235,900
+141,200
+149% +$2.75M ﹤0.01% 1619
2020
Q1 		$1.44M Buy
94,700
+49,053
+107% +$878K ﹤0.01% 2232
2019
Q4 		$1.05M Buy
45,647
+34,947
+327% +$776K ﹤0.01% 2610
2019
Q3 		$231K Buy
+10,700
New +$230K ﹤0.01% 3106

Other funds holding RYTM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jim Simons's RYTM Position: Q2 2026 in Review

Jim Simons reduced its Rhythm Pharmaceuticals (RYTM) stake by 74% in Q2 2026, selling an estimated $17.2M and leaving 68,281 shares worth $7.58M. The position accounts for 0.01% of the portfolio, ranked #1208.

Jim Simons first reported a position in RYTM in Q3 2019 and has held it in 15 quarters since. The position peaked at $55.2M in Q3 2025. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Jim Simons held 68,281 shares of Rhythm Pharmaceuticals worth $7.58M as of Q2 2026.
  • Jim Simons sold 189,730 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $17.2M.
  • Rhythm Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1208 holding.
  • Jim Simons first reported a position in Rhythm Pharmaceuticals in Q3 2019 and has held it in 15 quarters since.
  • Jim Simons's Rhythm Pharmaceuticals position peaked at $55.2M in Q3 2025.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.